---
title: "Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292794533.md"
description: "Abbott Laboratories (ABT) reports Q2 earnings on July 15, with analysts expecting EPS of $1.28 (+1.6%) and revenue of $12.52B (+12.4%). Growth is driven by the Exact Sciences acquisition, particularly its CancerGuard test. While Seeking Alpha rates ABT a Buy based on long-term MCED potential, Baird models more modest comparable growth of 4-4.5% for Q2. Despite beating estimates historically, ABT's stock has declined 29% year-to-date."
datetime: "2026-07-15T16:01:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292794533.md)
  - [en](https://longbridge.com/en/news/292794533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292794533.md)
generator: "portal-rs"
---

# Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition


### Related Stocks

- [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

- [27,113 Shares in Abbott Laboratories $ABT Acquired by Frazier Financial Advisors LLC](https://longbridge.com/en/news/297417441.md)
- [First National Bank of Omaha Sells 33,110 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/297396125.md)
- [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [Edmond DE Rothschild Holding S.A. Acquires Shares of 154,431 Abbott Laboratories $ABT](https://longbridge.com/en/news/297417415.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**